Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. - Wikidata - awgldk - TriplyDB

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

http://www.wikidata.org/entity/Q34464997

about

The HIV antiretroviral drug efavirenz has LSD-like properties Depressogenic effects of medications: a review Antiretroviral medication: an emerging category of prescription drug misuse Efavirenz and the CNS: what we already know and questions that need to be answered HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data.Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.Neurological and psychiatric adverse effects of antiretroviral drugs.Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells.Efavirenz modulation of sleep spindles and sleep spectral profile.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.Neuropsychiatric Effects of HIV Antiviral Medications.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Central nervous system disorders after starting antiretroviral therapy in South Africa.Pharmacogenomics of antimicrobial agents.Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda Mitochondrial (dys)function - a factor underlying the variability of efavirenz-induced hepatotoxicity?CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Long-term safety from the raltegravir clinical development program.Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014.A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.Neuropsychiatric side effects of efavirenz therapy.Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.Antiretroviral therapy and central nervous system HIV type 1 infection

P2860

Q24608183-CE853563-CFB1-46E0-9F14-A5D77CF188C8 Q24635465-35FDAF4D-B59B-4DE4-864B-AEB54223AEC6 Q26852974-AB3308F6-8992-4734-B45A-842FE4566215 Q28085028-A8490007-E24E-492F-9589-465705FF8F3F Q28539550-23B3037A-9437-42FD-BAAC-61B7C2501D57 Q28548473-9CCB5E6D-FFA0-404C-A715-BE2DACFADC1E Q28548638-B5C3F659-5C63-41A5-9E38-2087140FB805 Q31040458-40AB4735-357F-4660-8AB2-D33D109A8E2A Q33909996-670B7A28-12E1-4628-9947-D784091173ED Q34035045-8CC7FEF2-11E7-4937-88C0-3BB4EBA94511 Q34039419-003FFE63-DA80-4309-912C-E823611CA238 Q34219621-4ACD4E2D-6784-4517-9BDC-05B51AD2E761 Q34433247-E4EE9773-7CDC-4CDD-969F-7A0F33C8F91F Q34443184-B6B6EA36-25B8-4D04-9D2D-09F02967844F Q34531724-F774686F-723B-4EC4-9571-F7C40F5E622F Q34537705-421C616E-F365-4DA1-9884-8913A4CD9118 Q34756398-DC5EA91A-01C0-4D74-981A-75D4868FFA80 Q34799534-F5D75A28-810A-4B6A-A219-AE4BA80D6846 Q34977413-9999E885-7D35-42E8-9E0E-1069D28815CC Q35018246-151AB635-8399-431B-A26A-3216772A3D15 Q35132410-2082BB6F-C680-40F5-964B-690C4FCF0B69 Q35154032-6E228DCB-246D-4CF0-9421-818511007A5A Q35223924-C28D1D5D-1EC6-4270-8AC4-2651FB15DAC4 Q35518558-2D0CA099-1948-4EFB-B11E-5E0C2374BC0D Q35701258-093EC1E1-2578-489F-8219-69FF71E363C8 Q35947529-B99BD290-9D27-4957-BDF5-D445C686D2D4 Q36024652-82BC679C-2FF9-41E2-AC3A-041316BF0F78 Q36062320-5A41BC6F-1ACE-43B4-A824-8C322803740D Q36263781-C74CB060-6274-4ADD-9074-B9899AD32477 Q36282702-EF9F6488-6B1D-4072-BE5E-C95D7D4F76A9 Q36305444-C5BB789B-D032-428B-AA21-5983B13CF730 Q36554279-05C90ECF-C82B-4F2A-B2B5-23B3766F90DD Q36664960-8C77DBE2-870D-40B4-8F8B-77E046425D0F Q36723853-75CF722F-B0E3-4DF9-BA3C-4103DC49FC2B Q36729929-70F4F8C5-7996-4A4A-BAFA-32F6E0DFE5D4 Q36762436-10155EF7-D05E-43EE-98EB-FE77A9493665 Q36801543-17213871-C5F4-4A53-BDD0-A1FBC1D0F1CB Q36922243-AE4F85B2-C479-4E3E-8605-CF62883C6802 Q37036991-776A1F6A-E53C-4F82-8959-749DC1B7BB2E Q37066982-1880E86A-AC8D-4444-A62D-AEE2E65C99C4

P2860

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

http://www.wikidata.org/entity/Q34464997

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@ast

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@en

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@nl

type

label

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@ast

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@en

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@nl

prefLabel

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@ast

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@en

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@nl

P1433

Q34464997-62784894-E0DC-480D-B2A8-205069D42C07

P1476

Q34464997-91797005-F7EC-4BD9-87C3-6F9CB4982B7A

P2093

Q34464997-006DFDB4-3678-4F8E-A0EB-F49A2282FEB5

Q34464997-1C0CE5D7-B8BB-4436-A650-0E22F65298B5

Q34464997-600CFDBE-3173-43E0-8D4F-9F30C5ACEF60

Q34464997-A1DB95DF-65F6-4B25-A5AB-A8F21DF359A2

Q34464997-EA0F0D09-A371-49B4-B9B4-894D0C424119

Q34464997-EFD696C9-F364-4FAA-AADF-B7375A495DC8

Q34464997-FE253672-6BD3-438D-A569-DA288C583194

P2860

Q34464997-0E9EC800-BF27-4B4C-B709-6CF16906E3EC

Q34464997-13C24EA9-5CA9-4C7B-B7F4-116C82A03CB6

Q34464997-2154DFDF-515F-46D9-90A8-E63729877046

Q34464997-41A7C998-D721-4A21-9FFF-975D26ABC2B5

Q34464997-6426A574-19F6-4EC3-891A-4936BAD2F4E8

Q34464997-6A5316EA-A9EC-4D76-B25F-7496CA723342

Q34464997-72CECD1D-0954-435B-8EB9-FB42198C2CD8

Q34464997-8982DBA3-3ABE-4FE7-BCEA-9516630CB38D

Q34464997-8C343309-F92C-4328-BE2D-C74064816755

Q34464997-953E17A0-FEE5-4040-86A7-C0E5F0D3190C

P304

Q34464997-E5AA21AC-C145-4637-A320-E6B395E86804

P31

Q34464997-A6E1EF9A-06A4-4EDB-A9DF-3A7C89047D5E

P356

Q34464997-679E1DCB-A22F-4EBA-8C12-B4A0AB115976

P407

Q34464997-5B00332B-8D63-4C46-8301-B15701FCA490

P433

Q34464997-7777DF62-7466-4045-BEAD-DE97317043FE

P478

Q34464997-1AC0E035-5D98-4B22-A0EC-B539D1045762

P577

Q34464997-7A312A08-0AA9-4D89-BEE1-9F13FFEA98FD

P5875

Q34464997-36628DA5-6706-47B7-9718-258EC92E732B

P698

Q34464997-F7994D9C-3B60-4443-93EC-18002454FEF9

P356

P1433

Clinical Infectious Diseases

P1476

Prediction of neuropsychiatric ...... plasma drug level monitoring.

@en

P2093

Alberto Martín-Hidalgo

http://www.w3.org/2001/XMLSchema#string

Andrés Navarro

http://www.w3.org/2001/XMLSchema#string

Félix Gutiérrez

http://www.w3.org/2001/XMLSchema#string

Joaquín Borrás

http://www.w3.org/2001/XMLSchema#string

Mar Masiá

http://www.w3.org/2001/XMLSchema#string

Rosa Antón

http://www.w3.org/2001/XMLSchema#string

Sergio Padilla

http://www.w3.org/2001/XMLSchema#string

P2860

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients.

Management of sudden psychiatric disorders related to efavirenz.

Higher efavirenz plasma levels correlate with development of insomnia.

Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study.

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz.

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.

P304

1648-1653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/497835

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7499823

http://www.w3.org/2001/XMLSchema#string

P698

16267739

http://www.w3.org/2001/XMLSchema#string